antineoplastic agents Flashcards
Cancer Pathophysiology
Dysregulation of cell cycle
Continuous growth and division
Imbalance between oncogene expression and tumor suppressor gene expression
Tumor development
antineoplastic agents MOA
Stop or slow growth of cancer cells, which grow and divide quickly
Also affect healthy cells that grow quickly
Bone marrow cells
Cells of the gastrointestinal (GI) tract including cells that line the mouth and intestines
Hair
antineoplastic agents adverse effects
Bone marrow suppression (BMS)/myelosuppression
Neutropenia, anemia, thrombocytopenia
Nausea, vomiting, diarrhea, mucositis
Alopecia
antineoplastic agents counseling
Watch for fever, malaise, sore mouth or throat
May cause hair loss
antineoplastic agents interactions
Vaccines:
Inactivated
Live
antineoplastic agents key points
Monitor for signs of BMS and infection Often give antiemetics for N/V Dosing: Body surface area (BSA) Adjustments
Cyclophosphamide Alkylating Agents MOA
Forms strong covalent bonds with DNA inhibiting replication and causing bond breaks and cell death.
Cyclophosphamide Alkylating Agents uses
Cancers, autoimmune disorders
Cyclophosphamide Alkylating Agents dosing
Dosage forms: injection, tablets
Usual doses: 400-1800 mg/m2 IV x 1 dose that may be repeated at 2-4 week intervals, 50-100 mg/m2 PO daily for up to 14 continuous days
Cyclophosphamide Alkylating Agents adverse effects
BMS, N/V/D/mucositis, alopecia, hemorrhagic cystitis
Amenorrhea, sterility, secondary malignancies
Cyclophosphamide Alkylating Agents Hemorrhagic cystitis
Acrolein metabolite binds to bladder wall
Cystitis with tissue edema, ulceration, local hemorrhage
Painful urination, hematuria
Prevention:
Hydration
Mesna
Cyclophosphamide Alkylating Agents counseling
Drink plenty of fluids
Take oral doses early in the day
Report painful urination, discolored or bloody urine
Cyclophosphamide Alkylating Agents key points
Hydration ± Mesna to prevent hemorrhagic cystitis
Give antiemetics to prevent N/V
Doxorubicin Anthracyclines MOA
Inhibition of DNA and RNA synthesis by intercalation of DNA base pairs and inhibition of DNA repair by topoisomerase
Doxorubicin Anthracyclines uses
Cancers
Doxorubicin Anthracyclines dosing
Dosage forms: injection
Usual doses: 60-75 mg/m2 per dose every 3-4 weeks; 20-30 mg/m2 per day for 3 days every 4 weeks; 60 mg/m2 per dose every 2 weeks (dose dense
Doxorubicin Anthracyclines adverse effects
BMS, N/V/D/mucositis, alopecia, cardiotoxicity
Extravasation
Amenorrhea, sterility, secondary malignancies